Sanara MedTech Inc.

Listed Company
SMTICIK 0000714256NasdaqNon-AcceleratedSmaller ReportingOrthopedic, Prosthetic & Surgical Appliances & SuppliesTexasFY ends Dec 31
Period
FY 2025
Revenue
$103.12M
Net Income
$-37.56M
Total Assets
$72.94M
Equity
$5.94M
Shares Out
9.17M
Op. Cash Flow
$6.79M

Business

Sanara MedTech Inc. is a medical technology company that develops and commercializes technologies to improve clinical outcomes and reduce healthcare costs in surgical, chronic wound and skincare markets. It offers surgical and wound care products such as CellerateRX Surgical, BIASURGE, FORTIFY products, bone grafts like BiFORM and ALLOCYTE Plus, and a value‑based wound care program with Care Hub, an MSO network and a technology platform. The company operates through two reportable segments, Sanara Surgical and Tissue Health Plus (THP), and maintains in‑house R&D and partnerships. Its products and services are marketed primarily in the United States to hospitals, ambulatory surgical centers, physician offices, skilled nursing and home‑based care providers, via distributors, field sales representatives and payer or provider contracts.

Summary from filing dated 2025-03-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts
ConceptTrend
FY 2025
2025-12-31
FY 2024
2024-12-31
FY 2023
2023-12-31
FY 2022
2022-12-31
FY 2021
2021-12-31
Net Revenue10387654624
Cost of goods sold88862
Gross profit9679573922
Selling, general and administrative7972574628
Research and development5343558,704
Depreciation and amortization3342596,975
Change in fair value of earnout liabilities−14,451
Asset impairment charges2
Total operating expenses8877615229
Operating income71−4−13−7
Interest expense−7−3−475,783−711
Share of losses from equity method investments−952,466−90,007−379,633−616,927
Interest income3,67221,978
Gain on disposal of property and equipment10,932
Total other income (expense)−8−3−224,749−1−617,638
Net loss from continuing operations−393,124−2
Net loss from discontinued operations (including asset impairment charge of $26,472,407 in 2025) (Note 3)−37−8
Net loss−38−10−4−8−8
Net loss attributable to noncontrolling interest from continuing operations−5,441−3,224
Net loss attributable to noncontrolling interest from discontinued operations−244,127
Less: Total net loss attributable to noncontrolling interest−5,441−247,351−136,705−154,831−71,881
Net loss attributable to Sanara MedTech shareholders−38−10−4−8−8
Continuing operations, basic−0.05−0.23
Continuing operations, diluted−0.05−0.23
Discontinued operations, basic−4.31−0.91
Discontinued operations, diluted−4.31−0.91
Net loss per share of common stock, basic−4.36−1.14−0.52−1−1.08
Net loss per share of common stock, diluted−4.36−1.14−0.52−1
Weighted average number of common shares outstanding, basic98887
Weighted average number of common shares outstanding, diluted9888

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro